4-Amino-5-pyrimidinecarboxamide → HCID 135923522, 화합물

HRID 2076817

반응식

HRID 2076817 반응식
[NH2:1][C:2]1[C:7]([C:8]([NH2:10])=[O:9])=[CH:6][N:5]=[CH:4][N:3]=1.CO[C:13](=O)[CH2:14][O:15][CH2:16][CH2:17][C:18]1[CH:23]=[CH:22][CH:21]=[C:20]([F:24])[CH:19]=1.[Li+].C[Si]([N-][Si](C)(C)C)(C)C>C1COCC1>[F:24][C:20]1[CH:19]=[C:18]([CH2:17][CH2:16][O:15][CH2:14][C:13]2[NH:10][C:8](=[O:9])[C:7]3[C:2]([N:1]=2)=[N:3][CH:4]=[N:5][CH:6]=3)[CH:23]=[CH:22][CH:21]=1

참가 물질

5

반응물 3

HCID 8182124-Amino-5-pyrimidinecarboxamideHCID 2733832Lithium HexamethyldisilazideHCID 67099252HCID 67099252, 화합물

생성물 1

HCID 135923522HCID 135923522, 화합물수율 1%

시약·촉매·용매 1

HCID 8028Tetrahydrofuran용매

실험 절차

A suspension of the commercially available 4-amino-5-pyrimidinecarboxamide [4786-51-0] (150 mg, 1.09 mmol) and of [2-(3-fluoro-phenyl)-ethoxy]-acetic acid methyl ester (254 mg, 1.19 mmol) in THF (7 ml) was treated with LiHMDS (1M solution in THF, 2.17 ml) and stirred overnight at ambient temperature. The resulting yellow suspension was filtered and the filtrate was evaporated to dryness and triturated with EtOAc/MeOH 9:1. The yellow solid was filtered off, the mother-liquid was evaporated and the remaining residue was purified by column chromatography (silica gel, EtOAc/MeOH, 9:1) to give the title compound as a white solid (3 mg, 1%), MS: m/e=301.1 [M+H+].

후처리

  1. filtrationThe resulting yellow suspension was filtered
  2. customthe filtrate was evaporated to dryness
  3. customtriturated with EtOAc/MeOH 9:1
  4. filtrationThe yellow solid was filtered off
  5. customthe mother-liquid was evaporated
  6. customthe remaining residue was purified by column chromatography (silica gel, EtOAc/MeOH, 9:1)

출처 및 근거

ORD 기록
ord-774e415be8b145c5b0dc18578322c24b
출처 데이터셋
uspto-grants-2011_04
특허 번호
US07928106B2

연결된 노트

불러오는 중…